Hospital
Honorhealth
Honorhealth was paid $7.44M by Medicaid between Jan 2018 and Dec 2024, across 127 billing codes. Its largest line is 99285, emergency room visit (most serious) — 26% of everything it billed.
33Billing provider infoHONORHEALTH
SCOTTSDALE, AZ 85255
SCOTTSDALE, AZ 85255
33aNPI1417152745assigned 06/18/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.44M
24GClaims272,148
24DCodes billed127
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#49 of 78
Median peer was paid$12.21M
This provider vs. median0.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 32,169 | $893K | |
| 2019 | 36,135 | $912K | |
| 2020 | 36,888 | $1.07M | |
| 2021 | 40,387 | $1.09M | |
| 2022 | 45,247 | $1.16M | |
| 2023 | 45,957 | $1.23M | |
| 2024incomplete | 35,365 | $1.08M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 26% | 6,228 | 5,624 | $1.97M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 5,784 | 5,368 | $1.03M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 6,366 | 5,893 | $867K |
| G0378 | Hospital observation service, per hour | 9.6% | 9,283 | 3,404 | $712K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 8.5% | 2,623 | 2,426 | $631K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 7.6% | 8,872 | 2,728 | $567K |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.7% | 6,490 | 4,704 | $351K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.9% | 2,834 | 2,645 | $291K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.5% | 6,136 | 1,981 | $187K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 2,505 | 2,326 | $175K |
| 72125 | Computed tomography, cervical spine; without contrast material | 2.1% | 355 | 333 | $159K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.7% | 640 | 597 | $123K |
115 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.0% | 83 | $75K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 631 | $72K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,255 | $51K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,384 | $47K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 410 | $20K |
| 97161 | <1% | 1,517 | $19K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 353 | $17K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 35 | $12K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 623 | $9K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 772 | $7K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 832 | $6K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,317 | $6K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 7,044 | $6K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,031 | $6K |
| 80053 | Comprehensive metabolic panel | <1% | 10,482 | $4K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 110 | $2K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,896 | $2K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 560 | $2K |
| 96376 | <1% | 3,988 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,632 | $2K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,970 | $1K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,260 | $1K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,217 | $1K |
| 84484 | <1% | 6,504 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,829 | $1K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,093 | $1K |
| 97165 | <1% | 45 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,933 | $724.70 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,489 | $662.27 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,395 | $551.65 |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 52 | $421.03 |
| 80306 | <1% | 1,392 | $408.36 | |
| 81001 | <1% | 7,299 | $393.82 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,854 | $374.85 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,833 | $344.60 |
| 83690 | <1% | 4,663 | $313.15 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,898 | $285.14 |
| 81025 | <1% | 1,976 | $277.10 | |
| 87040 | <1% | 1,149 | $240.17 | |
| 94760 | <1% | 6,067 | $231.08 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 122 | $189.90 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,355 | $182.90 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,725 | $175.59 |
| 83735 | <1% | 3,879 | $172.15 | |
| 82248 | <1% | 3,797 | $153.07 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 131 | $149.96 |
| 85730 | <1% | 1,168 | $149.34 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,307 | $146.53 |
| 85379 | <1% | 1,369 | $140.19 | |
| 97116 | <1% | 237 | $123.72 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,542 | $117.66 |
| 84703 | <1% | 2,445 | $106.51 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,829 | $105.87 |
| 83605 | <1% | 1,166 | $97.86 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,912 | $97.26 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 804 | $94.77 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,097 | $86.80 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,353 | $83.87 |
| 82962 | <1% | 5,506 | $81.77 | |
| 82550 | <1% | 588 | $77.13 | |
| 83880 | <1% | 681 | $76.47 | |
| 85027 | <1% | 4,981 | $71.29 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 317 | $71.18 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,105 | $60.74 |
| 87186 | <1% | 389 | $58.50 | |
| 85610 | <1% | 3,332 | $58.20 | |
| 87077 | <1% | 558 | $47.59 | |
| 86900 | <1% | 67 | $31.82 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12 | $24.94 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12 | $24.86 |
| 80329 | <1% | 436 | $24.22 | |
| 80320 | <1% | 1,657 | $24.22 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,883 | $22.74 |
| 84100 | <1% | 494 | $22.61 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 787 | $22.53 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,501 | $18.97 |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 14 | $13.51 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 21 | $12.49 |
| A9270 | Non-covered item or service | <1% | 2,551 | $12.02 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 93 | $5.08 |
| 87205 | <1% | 146 | $3.57 | |
| 84132 | <1% | 391 | $3.44 | |
| J3490 | Unclassified drugs | <1% | 100 | $2.17 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 1,240 | $0.00 |
| C1769 | Guide wire | 0% | 560 | $0.00 |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 162 | $0.00 |
| 87070 | 0% | 55 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 1,982 | $0.00 |
| 93971 | 0% | 71 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 402 | $0.00 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 14 | $0.00 |
| 86901 | 0% | 107 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 87 | $0.00 |
| 88342 | 0% | 75 | $0.00 | |
| 86140 | 0% | 87 | $0.00 | |
| 87081 | 0% | 17 | $0.00 | |
| 85652 | 0% | 41 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 25 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 15 | $0.00 |
| 87400 | 0% | 292 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 571 | $0.00 |
| 80061 | Lipid panel | 0% | 72 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 92 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 719 | $0.00 |
| 99152 | 0% | 89 | $0.00 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 270 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 38 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 30 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 18 | $0.00 |
| 81003 | 0% | 13 | $0.00 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 26 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 15 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 75 | $0.00 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 26 | $0.00 |
| 96367 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHENDRIX, JENIFER (SENIOR NETWORK DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Honorhealth | Phoenix, AZ | $107.15M |
| Honorhealth | Phoenix, AZ | $65.78M |
| Honorhealth | Scottsdale, AZ | $47.05M |
| Honorhealth | Scottsdale, AZ | $23.83M |
| Honorhealth | Phoenix, AZ | $7.97M |
| Honorhealth | Surprise, AZ | $3.33M |
| Honorhealth | Scottsdale, AZ | $232K |
| Honorhealth | Scottsdale, AZ | $13K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.